Complement C1 inhibitor protein - CSL Behring

Drug Profile

Complement C1 inhibitor protein - CSL Behring

Alternative Names: Berinert; Berinert HS; Berinert P; C1 esterase inhibitor - CSL Behring; C1 esterase inhibitor concentrate; C1 inaktivator HS; C1-INH - CSL Behring; CE 1145; Complement C1 inactivator - CSL Behring; CSL 830; Human C1 esterase inhibitor concentrate

Latest Information Update: 11 Nov 2016

Price : $50

At a glance

  • Originator CSL Behring
  • Class Complement C1 inactivator proteins; Vascular disorder therapies
  • Mechanism of Action Complement C1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Angioedema
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Hereditary angioedema
  • Phase I/II Transplant rejection
  • Discontinued Reperfusion injury; Septic shock; Vascular disorders

Most Recent Events

  • 11 Nov 2016 CSL Behring plans a clinical trial for Reperfusion injury in Switzerland
  • 30 Aug 2016 The US FDA accepts BLA for complement C1 inhibitor protein (SC) for Hereditary angiodema (Prevention) for review
  • 01 Aug 2016 Preregistration for Hereditary angioedema (In adolescents, Prevention, In adults) in USA (SC) before August 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top